Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) EBT (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed EBT for 7 consecutive years, with $40.8 million as the latest value for Q4 2025.

  • Quarterly EBT fell 27.42% to $40.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $215.1 million through Dec 2025, up 12.13% year-over-year, with the annual reading at $215.1 million for FY2025, 12.13% up from the prior year.
  • EBT hit $40.8 million in Q4 2025 for Harmony Biosciences Holdings, down from $67.5 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $67.5 million in Q3 2025 to a low of -$10.5 million in Q3 2021.
  • Historically, EBT has averaged $36.1 million across 5 years, with a median of $40.2 million in 2023.
  • Biggest YoY gain for EBT was 59688.89% in 2021; the steepest drop was 651.18% in 2021.
  • Year by year, EBT stood at $24.5 million in 2021, then skyrocketed by 80.2% to $44.1 million in 2022, then dropped by 10.01% to $39.7 million in 2023, then skyrocketed by 41.49% to $56.2 million in 2024, then dropped by 27.42% to $40.8 million in 2025.
  • Business Quant data shows EBT for HRMY at $40.8 million in Q4 2025, $67.5 million in Q3 2025, and $49.6 million in Q2 2025.